EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lucchi, M.
Right arrow Articles by Angeletti, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lucchi, M.
Right arrow Articles by Angeletti, C. A.

European Journal of Cardio-Thoracic Surgery, Vol 12, 689-693, Copyright © 1997 by European Association for Cardio-thoracic Surgery

ARTICLES

Surgery in the management of small cell lung cancer

M Lucchi, A Mussi, A Chella, A Janni, A Ribechini, GF Menconi and CA Angeletti
Service of Thoracic Surgery, Department of Surgery, University of Pisa, Italy.

OBJECTIVE: We analyzed our experience in the period January 1975- December 1995 aiming to confirm the role of surgery in the multimodality treatment of small cell lung cancer (SCLC). METHODS: 127 patients (5.28% of the overall lung resections for carcinoma) underwent surgery for SCLC. The median age was 60 years (range 34-73). In 87 patients (68.5%) a pre-operative tissue diagnosis was effected and those patients underwent a complete staging procedure. Fifteen patients received up to six complete courses of neoadjuvant and adjuvant chemotherapy. The surgical procedures included: 50 pneumonectomies, 71 lobectomies and six wedge resections. Two patients experienced a local recurrence and a completion pneumonectomy was performed. RESULTS: The median follow-up is 66 months (range 6-214). The 5-year actuarial survival rate is 22.6% (median 18 months). Twenty-three patients are still alive, 21 of them being disease-free. Considering the most conspicuous group of patients (n = 92) treated by surgery and adjuvant chemotherapy, the survival data were 47.2, 14.8 and 14.4% for Stage I, II and III, respectively (P = 0.001). NO patients had a significantly better survival than N1 and N2 patients (P = 0.035). CONCLUSIONS: Surgery and adjuvant chemotherapy might represent an effective form of treatment of limited SCLC without lymph-node involvement. The role of surgery is yet to be verified as regards N1 and N2 status, where even neoadjuvant chemotherapy has not achieved the hoped-for results (no patient reaching a 2-year survival).


This article has been cited by other articles:


Home page
 ChestHome page
G. R. Simon and A. Turrisi
Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest, September 1, 2007; 132(3_suppl): 324S - 339S.
[Abstract] [Full Text] [PDF]

Home page
 ICVTSHome page
M. Sakai, S. Ishikawa, T. Yamamoto, M. Onizuka, Y. Sakakibara, T. Iijima, and M. Noguchi
Preoperative TNM evaluation of peripheral clinical stage I small cell lung cancer treated by initial lobectomy with adjuvant chemotherapy
Interactive CardioVascular and Thoracic Surgery, April 1, 2005; 4(2): 118 - 122.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. V. Brock, C. M. Hooker, J. E. Syphard, W. Westra, L. Xu, A. J. Alberg, D. Mason, S. B. Baylin, J. G. Herman, R. C. Yung, et al.
Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come
J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 64 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
H. Rostad, A. Naalsund, R. Jacobsen, T. E. Strand, H. Scott, E. H. Strom, and J. Norstein
Small cell lung cancer in Norway. Should more patients have been offered surgical therapy?
Eur. J. Cardiothorac. Surg., October 1, 2004; 26(4): 782 - 786.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
A. Badzio, K. Kurowski, H. Karnicka-Mlodkowska, and J. Jassem
A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer
Eur. J. Cardiothorac. Surg., July 1, 2004; 26(1): 183 - 188.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. R. Simon and H. Wagner
Small Cell Lung Cancer
Chest, January 1, 2003; 123(1_suppl): 259S - 271S.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
M. Lucchi, A. Mussi, G. Fontanini, P. Faviana, A. Ribechini, and C. A. Angeletti
Small cell lung carcinoma (SCLC): the angiogenic phenomenon
Eur. J. Cardiothorac. Surg., June 1, 2002; 21(6): 1105 - 1110.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
R. Komaki, M. H. Chasen, W. D. Travis, J. B. Putnam, F. V. Fossella, R. W. Byhardt, and J. Y. Ro
Oncodiagnosis Panel: 1999: Cancer of the Lung: Oncodiagnosis
RadioGraphics, November 1, 2001; 21(6): 1573 - 1596.
[Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
T. Lewinski, M. Zulawski, C. Turski, and A. Pietraszek
Small cell lung cancer I-III A: cytoreductive chemotherapy followed by resection with continuation of chemotherapy
Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 391 - 398.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. R. Wick and J. H. Ritter
Neuroendocrine neoplasia of the lung
Ann. Thorac. Surg., January 1, 2000; 69(1): 307 - 308.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1997 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.